Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In June 2021, the ACR released an updated guideline for the treatment of rheumatoid arthritis. The guideline underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Meanwhile, the most recent research in RA is explored by expert Jeffrey Curtis, MD, MS, MPH.
FEATURED ARTICLE: Patients with RA in the Setting of Cardiovascular Disease
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
How can we best care for our patients from a joint & cardiovascular perspective? That’s the question Christina Charles-Schoeman, MD, MS, professor of medicine and chief, Division of Rheumatology, University of California Los Angeles Medical Center, Santa Monica, Calif., addressed in a session at ACR Convergence 2024.
In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
The goal is to identify people at risk for RA &, perhaps, prevent its onset.
The session highlighted the importance of correctly identifying and treating patients with RA-ILD early in their disease course.
In a session on a current ACR project on musculoskeletal ultrasound (MSUS), Gurjit Kaeley, MBBS, RhMSUS, MRCP, division chief, professor of medicine, fellowship program director and program director for musculoskeletal ultrasound at the University of Florida College of Medicine, Jacksonville, will present information on proposed guidance related to rheumatoid arthritis. The ACR places a high…
With thousands of research abstracts and posters being presented at ACR Convergence 2024, Nov. 14–19, at the Walter E. Washington Convention Center in Washington, D.C., figuring out which research is important today, which could prove important in the future, what has the potential to affect clinical care or prove the basis for future research is…
On Sunday, Nov. 17, at ACR Convergence 2024, three speakers will deliver a presentation on Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping. This session will have three 20-minute presentations that cover distinct aspects of RA-associated ILD from early identification of ILD through high-resolution computed tomography (HRCT) text mining, to phenotyping…
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
Rheumatoid arthritis (RA) is treatable, and for that, we should be grateful. But wouldn’t it be better if we could prevent it from even happening? Recent data from a study in China demonstrated some interesting results. Could an older type of diabetes medication be the answer we’ve been looking for? Background Preclinical studies have suggested…
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
SAN DIEGO—Older adults with rheumatoid arthritis (RA) comprise two groups: those who have lived with diagnosed RA since an early age (young-onset RA) and those who have new-onset RA diagnosed at an older age (≥65 years), known as late-onset RA or, formerly, as elderly onset RA.1 Individuals with late-onset RA have more acute and systemic…
Difficult-to-treat rheumatoid arthritis (RA) is defined as the failure of two or more classes of biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) to control active or progressive disease in patients with RA. Between 5 and 20% of patients with RA have difficult-to-treat RA.